atezolizumab + carboplatin + docetaxel + pertuzumab + trastuzumab + trastuzumab emtansine

This is a **combination regimen** consisting of six anticancer agents: atezolizumab (an anti–PD-L1 antibody checkpoint inhibitor), carboplatin (a platinum-based DNA crosslinking chemotherapy), docetaxel (a taxane microtubule inhibitor chemotherapy), pertuzumab (a monoclonal antibody targeting HER2 dimerization), trastuzumab (a monoclonal antibody targeting HER2 extracellular domain), and trastuzumab emtansine (an antibody–drug conjugate of trastuzumab linked to the cytotoxic agent DM1). This intensive combination is potentially used for the treatment of breast cancers, specifically metastatic triple-negative and HER2-positive subtypes. The regimen combines immunotherapy, cytotoxic chemotherapy, dual HER2 blockade, and antibody–drug conjugate therapy, targeting tumor cell proliferation, immune evasion, and HER2-dependent oncogenic signaling[1][2][3][4][5].